MUMBAI, India, Sept. 22 -- Intellectual Property India has published a patent application (202617086162 A) filed by Boehringer Ingelheim International Gmbh on July 14, 2026, for Anti-Cancer Combination Therapy.
Inventors include Augsten, Martin; Baum, Anke; Chylinski, Krzysztof; and Waizenegger, Irene.
The application for the patent was published on September 18, 2026, under issue no. 38/2026.
Abstract: The present invention refers to the combination of the HER2 tyrosine kinase inhibitor zongertinib with an anti-HER2 antibody and/or an anti-HER2 antibody-drug conjugate. Such combination may further comprise an additional anti-cancer medicament. The combination of the invention is useful for the treatment and/or prevention of oncological ...